Zanu­bru­ti­nib Ver­sus Ibru­ti­nib in Sym­pto­ma­tic Wal­den­ström Macro­glo­bu­li­ne­mia: Final Ana­ly­sis From the Ran­do­mi­zed Phase III ASPEN Study.

Dimo­pou­los MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marl­ton P, Wahlin BE, Garcia-​Sanz R, McCar­thy H, Mul­ligan S, Tede­schi A, Cas­tillo JJ, Czyz J, Fernández de Lar­rea C, Belada D, Libby E, Matous J, Motta M, Sid­diqi T, Tani M, Trněný M, Min­nema MC, Buske C, Leblond V, Treon SP, Trot­man J, Chan WY, Schnei­der J, Alle­welt H, Patel S, Cohen A, Tam CS.J Clin Oncol. 2023 Jul 21:JCO2202830. doi: 10.1200/JCO.22.02830. Online ahead of print.PMID: 37478390

Obi­nu­tu­zu­mab Ver­sus Ritu­xi­mab Immu­n­o­chemo­the­rapy in Pre­viously Untrea­ted iNHL: Final Results From the GAL­LIUM Study.

Town­send W, Hid­de­mann W, Buske C, Car­tron G, Cun­ning­ham D, Dyer MJS, Grib­ben JG, Phil­lips EH, Drey­ling M, Sey­mour JF, Grigg A, Trot­man J, Lin TY, Hong XN, King­biel D, Niel­sen TG, Knapp A, Herold M, Mar­cus R.Hemas­phere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919. eColl­ec­tion 2023 Jul.PMID: 37404773 

Reply to S. Saro­siek et al.

Buske C, Dimo­pou­los MA, Morel P; European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia (ECWM).J Clin Oncol. 2023 Jun 22:JCO2300877. doi: 10.1200/JCO.23.00877. Online ahead of print.PMID: 37348018 
 

SARS-​CoV-2 Infec­tion in Pati­ents With Wal­den­ström's Macro­glo­bu­li­ne­mia: A Mul­ti­cen­ter Inter­na­tio­nal Cohort Study.

Defran­cesco I, Fer­retti VV, Morel P, Kyria­kou C, Kas­tri­tis E, Tohidi-​Esfahani I, Tede­schi A, Buske C, García-​Sanz R, Vos JMI, Peri V, Mar­giotta Casa­luci G, Fer­rari A, Piazza F, Oost­vo­gels R, Lovato E, Mon­tes L, Forne­cker LM, Gru­nen­berg A, Dimo­pou­los MA, Tam CS, D'Sa S, Leblond V, Trot­man J, Pas­sa­monti F, Arcaini L, Varet­toni M.Hemas­phere. 2023 Jun 2;7(6):e887. doi: 10.1097/HS9.0000000000000887. eColl­ec­tion 2023 Jun.PMID: 37283569 
 

Future Direc­tions in the Front­line Manage­ment of Wal­den­ström Macro­glo­bu­li­ne­mia.

Buske C, Palomba ML.Hema­tol Oncol Clin North Am. 2023 Aug;37(4):719-725. doi: 10.1016/j.hoc.2023.05.001. Epub 2023 Jun 1.PMID: 37270384 
 

Report of con­sen­sus panel 2 from the 11th inter­na­tio­nal work­shop on Wal­den­ström's macro­glo­bu­li­ne­mia on the manage­ment of relap­sed or refrac­tory WM pati­ents.

D'Sa S, Matous JV, Advani R, Buske C, Cas­tillo JJ, Gatt M, Kapoor P, Kers­ten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Saro­siek S, Shad­man M, Tal­au­likar D, Tam CS, Tede­schi A, Tho­mas SK, Tohidi-​Esfahani I, Trot­man J, Varet­toni M, Vos J, Garcia-​Sanz R, San-​Miguel J, Dimo­pou­los MA, Treon SP, Kas­tri­tis E.Semin Hema­tol. 2023 Mar;60(2):80-89. doi: 10.1053/j.semin­he­ma­tol.2023.03.003. Epub 2023 Mar 27.PMID: 37147252
 

A non­ca­no­ni­cal enzy­ma­tic func­tion of PIWIL4 main­tains geno­mic inte­grity and leuke­mic growth in AML.

Bame­zai S, Pulik­kot­til AJ, Yadav T, Vegi NM, Muel­ler J, Mark J, Man­dal T, Feder K, Ihme S, Song C, Ros­ler R, Wiese S, Hoell JI, Klo­et­gen A, Kar­san A, Kumari A, Wojen­ski L, Sinha AU, Gonzalez-​Menendez I, Quintanilla-​Martinez L, Donato E, Trumpp A, Kruse E, Ham­perl S, Zou L, Rawat VPS, Buske C.Blood. 2023 Jul 6;142(1):90-105. doi: 10.1182/blood.2022018651.PMID: 37146239
 

Report of con­sen­sus panel 7 from the 11th inter­na­tio­nal work­shop on Wal­den­ström macro­glo­bu­li­ne­mia on prio­ri­ties for novel cli­ni­cal tri­als.

Tam CS, Kapoor P, Cas­tillo JJ, Buske C, Ansell SM, Bra­na­gan AR, Kimby E, Li Y, Palomba ML, Qiu L, Shad­man M, Abey­koon JP, Saro­siek S, Vos J, Yi S, Ste­phens D, Roos-​Weil D, Roc­caro AM, Morel P, Mun­shi NC, Ander­son KC, San-​Miguel J, Garcia-​Sanz R, Dimo­pou­los MA, Treon SP, Kers­ten MJ.Semin Hema­tol. 2023 Mar;60(2):118-124. doi: 10.1053/j.semin­he­ma­tol.2023.03.006. Epub 2023 Mar 24.PMID: 37099031

Gene­tic and Micro­en­vi­ron­ment Fea­tures Do Not Distin­guish Fol­li­cu­lar Lym­phoma Pati­ents Requi­ring Imme­diate or Defer­red Treat­ment.

Ste­vens WBC, Los-​de Vries GT, Langois-​Jacques C, Clear AJ, Sta­thi P, San­der B, Rosen­wald A, Cala­mi­nici M, Hos­ter E, Hid­de­mann W, Gau­lard P, Sal­les G, Klap­per W, Xerri L, Bur­ton C, Tooze RM, Smith AG, Buske C, Scott DW, Nat­kunam Y, Advani R, Sehn LH, Raema­ekers J, Grib­ben J, Lock­mer S, Kimby E, Kers­ten MJ, Maucort-​Boulch D, Yls­tra B, van Dijk E, de Jong D.Hemas­phere. 2023 Apr 5;7(4):e863. doi: 10.1097/HS9.0000000000000863. eColl­ec­tion 2023 Apr.PMID: 37038467 

Plain Lan­guage Sum­mary of the iNNO­VATE study: ibru­ti­nib plus ritu­xi­mab is well-​tolerated and effec­tive in people with Wal­den­ström's macro­glo­bu­li­ne­mia.

Buske C, Tede­schi A, Trot­man J, García-​Sanz R, Mac­Do­nald D, Leblond V, Mahe B, Her­baux C, Matous JV, Tam CS, Heff­ner LT, Varet­toni M, Palomba ML, Shus­tik C, Kas­tri­tis E, Treon SP, Ping J, Hauns B, Arango-​Hisijara I, Dimo­pou­los MA.Future Oncol. 2023 Feb;19(5):345-353. doi: 10.2217/fon-2022-1015. Epub 2023 Feb 23.PMID: 36815271 
 

Bortezomib-​Dexamethasone, Ritu­xi­mab, and Cyclo­phos­pha­mide as First-​Line Treat­ment for Wal­den­ström's Macro­glo­bu­li­ne­mia: A Pro­spec­tively Ran­do­mi­zed Trial of the European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia.

Buske C, Dimo­pou­los MA, Gru­nen­berg A, Kas­tri­tis E, Tomo­wiak C, Mahé B, Trous­sard X, Hajek R, Viar­dot A, Tour­nil­hac O, Aur­ran T, Lepretre S, Zerazhi H, Hivert B, Leblond V, de Gui­bert S, Bran­de­fors L, Garcia-​Sanz R, Gomes da Silva M, Kimby E, Schmelzle B, Kas­zyn­ski D, Drey­haupt J, Muche R, Morel P.J Clin Oncol. 2023 May 10;41(14):2607-2616. doi: 10.1200/JCO.22.01805. Epub 2023 Feb 10.PMID: 36763945 

Cor­ri­gen­dum to "Mar­gi­nal zone lym­pho­mas: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up": [Annals of Onco­logy 31 (2020) 17-29].

Zucca E, Arcaini L, Buske C, John­son PW, Pon­zoni M, Rade­rer M, Ricardi U, Salar A, Sta­ma­to­pou­los K, Thieb­le­mont C, Wothers­poon A, Ladetto M; ESMO Gui­de­li­nes Com­mit­tee. Elec­tro­nic address: cli­ni­cal­gui­de­li­nes@esmo.org.Ann Oncol. 2023 Mar;34(3):325. doi: 10.1016/j.annonc.2022.11.009. Epub 2022 Dec 16.PMID: 36529567 

Dia­gno­stics in Wal­den­ström's macro­glo­bu­li­ne­mia: a con­sen­sus state­ment of the European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia.

Dogliotti I, Jiménez C, Varet­toni M, Tal­au­likar D, Bagra­t­uni T, Fer­rante M, Pérez J, Drandi D, Puig N, Giles­tro M, García-​Álvarez M, Owen R, Jurczak W, Tede­schi A, Leblond V, Kas­tri­tis E, Kers­ten MJ, D'Sa S, Kaščák M, Wil­len­ba­cher W, Roc­caro AM, Pou­lain S, Morel P, Kyria­kou C, Fend F, Vos JMI, Dimo­pou­los MA, Buske C, Fer­rero S, García-​Sanz R.Leuke­mia. 2023 Feb;37(2):388-395. doi: 10.1038/s41375-022-01762-3. Epub 2022 Nov 26.PMID: 36435884 

Bruton tyro­sine kinase inhi­bi­tors in the manage­ment of Wal­den­ström macro­glo­bu­li­ne­mia.

Cas­tillo JJ, Buske C, Trot­man J, Saro­siek S, Treon SP.Am J Hema­tol. 2023 Feb;98(2):338-347. doi: 10.1002/ajh.26788. Epub 2023 Jan 1.PMID: 36415104

Mana­ging Wal­den­ström's macro­glo­bu­li­ne­mia with BTK inhi­bi­tors.

Buske C, Jurczak W, Salem JE, Dimo­pou­los MA.Leuke­mia. 2023 Jan;37(1):35-46. doi: 10.1038/s41375-022-01732-9. Epub 2022 Nov 19.PMID: 36402930 
 

Mosun­e­tu­zu­mab, a bispe­ci­fic anti­body, in pati­ents with relap­sed or refrac­tory fol­li­cu­lar lym­phoma.

Buske C. Lan­cet Oncol. 2022 Aug;23(8):967-969. doi: 10.1016/S1470-2045(22)00385-0. Epub 2022 Jul 5. PMID: 35803285 

Dia­gno­stics in Wal­den­ström's macro­glo­bu­li­ne­mia: a con­sen­sus state­ment of the European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia.

Dogliotti I, Jiménez C, Varet­toni M, Tal­au­likar D, Bagra­t­uni T, Fer­rante M, Pérez J, Drandi D, Puig N, Giles­tro M, García-​Álvarez M, Owen R, Jurczak W, Tede­schi A, Leblond V, Kas­tri­tis E, Kers­ten MJ, D'Sa S, Kaščák M, Wil­len­ba­cher W, Roc­caro AM, Pou­lain S, Morel P, Kyria­kou C, Fend F, Vos JMI, Dimo­pou­los MA, Buske C, Fer­rero S, García-​Sanz R. Leuke­mia. 2023 Feb;37(2):388-395. doi: 10.1038/s41375-022-01762-3. Epub 2022 Nov 26. PMID: 36435884

The EHA Rese­arch Road­map: Mali­gnant Lym­phoid Disea­ses.

Drey­ling M, André M, Gök­bu­get N, Tilly H, Jer­ke­man M, Grib­ben J, Fer­reri A, Morel P, Stil­gen­bauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bödör C, Burk­hardt B, Buske C, Dol­lo­res Cabal­lero M, Campo E, Cha­puy B, Davies A, de Leval L, Door­duijn J, Feder­ico M, Gau­lard P, Gay F, Ghia P, Grønbæk K, Gold­schmidt H, Kers­ten MJ, Kie­se­wet­ter B, Landman-​Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-​Guillermo A, Mac­in­tyre E, Man­tega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pos­pi­si­lova S, Pott C, Robak T, Spina M, Sta­ma­to­pou­los K, Stary J, Tarte K, Tede­schi A, Thieb­le­mont C, Trappe RU, Trüm­per LH, Sal­les G. Hemas­phere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eColl­ec­tion 2022 Jun. PMID: 35620592

Geno­mic and micro­en­vi­ron­men­tal land­s­cape of stage I fol­li­cu­lar lym­phoma, com­pa­red with stage III/IV.

Los-​de Vries GT, Ste­vens WBC, van Dijk E, Langois-​Jacques C, Clear AJ, Sta­thi P, Roe­mer MGM, Men­de­ville M, Hij­me­ring NJ, San­der B, Rosen­wald A, Cala­mi­nici M, Hos­ter E, Hid­de­mann W, Gau­lard P, Sal­les G, Horn H, Klap­per W, Xerri L, Bur­ton C, Tooze RM, Smith AG, Buske C, Scott DW, Nat­kunam Y, Advani R, Sehn LH, Raema­ekers J, Grib­ben J, Kimby E, Kers­ten MJ, Maucort-​Boulch D, Yls­tra B, de Jong D. Blood Adv. 2022 Sep 27;6(18):5482-5493. doi: 10.1182/bloo­dad­van­ces.2022008355. PMID: 35816682

A phase-​II study of atez­oli­zu­mab in com­bi­na­tion with obi­nu­tu­zu­mab or ritu­xi­mab for relap­sed or refrac­tory man­tle cell or mar­gi­nal zone lym­phoma or Wal­den­ström's macro­glo­bu­li­ne­mia.

Panay­io­ti­dis P, Tumyan G, Thieb­le­mont C, Ptush­kin VV, Marin-​Niebla A, García-​Sanz R, Le Gouill S, Sta­t­his A, Bot­tos A, Hamidi H, Katz P, Per­retti T, Wil­lis JC, Buske C. Leuk Lym­phoma. 2022 May;63(5):1058-1069. doi: 10.1080/10428194.2021.2015765. Epub 2022 Jan 19. PMID: 35045765

SAKK 35/15: a phase 1 trial of obi­nu­tu­zu­mab in com­bi­na­tion with vene­toclax in pati­ents with pre­viously untrea­ted fol­li­cu­lar lym­phoma.

Sta­t­his A, Mey U, Schär S, Hitz F, Pott C, Mach N, Kras­niqi F, Novak U, Schmidt C, Hoh­loch K, Kienle DL, Hess D, Moc­cia AA, Unter­halt M, Eck­hardt K, Hayoz S, Fores­tieri G, Rossi D, Dirn­ho­fer S, Ceriani L, Sar­tori G, Ber­toni F, Buske C, Zucca E, Hid­de­mann W. Blood Adv. 2022 Jul 12;6(13):3911-3920. doi: 10.1182/bloo­dad­van­ces.2021006520. PMID: 35537101

Effi­cacy and Safety of CT-P10 Ver­sus Ritu­xi­mab in Untrea­ted Low-​Tumor-Burden Fol­li­cu­lar Lym­phoma: Final Results of a Ran­do­mi­zed Phase III Study.

Kwak LW, San­cho JM, Cho SG, Naka­zawa H, Suzu­miya J, Tumyan G, Kim JS, Menne T, Mariz J, Ilyin N, Jurczak W, Lopez Mar­ti­nez A, Samoi­lova O, Zhav­rid E, Yañez Ruiz E, Trneny M, Popp­le­well L, Ogura M, Kim WS, Lee SJ, Kim SH, Ahn KY, Buske C.Clin Lym­phoma Mye­loma Leuk. 2021 Aug 28:S2152-2650(21)00362-1.

Ibru­ti­nib Plus Ritu­xi­mab Ver­sus Pla­cebo Plus Ritu­xi­mab for Wal­den­ström's Macro­glo­bu­li­ne­mia: Final Ana­ly­sis From the Ran­do­mi­zed Phase III iNNO­VATE Study.

Buske C, Tede­schi A, Trot­man J, García-​Sanz R, Mac­Do­nald D, Leblond V, Mahe B, Her­baux C, Matous JV, Tam CS, Heff­ner LT, Varet­toni M, Palomba ML, Shus­tik C, Kas­tri­tis E, Treon SP, Ping J, Hauns B, Arango-​Hisijara I, Dimo­pou­los MA.J Clin Oncol. 2021 Oct 4:JCO2100838. doi: 10.1200/JCO.21.00838. Online ahead of print.

Long-​term effi­cacy and safety of CT-P10 or ritu­xi­mab in untrea­ted advan­ced fol­li­cu­lar lym­phoma: a ran­do­mi­zed phase 3 study.

Buske C, Jurczak W, San­cho JM, Zhav­rid E, Kim JS, Hernández-​Rivas JÁ, Prok­ha­rau A, Vasi­lica M, Nagar­kar R, Kwak L, Kim WS, Lee S, Kim S, Ahn K, Ogura M.Blood Adv. 2021 Sep 14;5(17):3354-3361. doi: 10.1182/bloo­dad­van­ces.2021004484.PMID: 34477816

TET3 pro­mo­tes AML growth and epi­ge­ne­ti­cally regu­la­tes glu­cose meta­bo­lism and leuke­mic stem cell asso­cia­ted pathways.

Pulik­kot­til AJ, Bame­zai S, Ammer T, Mohr F, Feder K, Vegi NM, Man­dal T, Kohl­ho­fer U, Quintanilla-​Martinez L, Sinha A, Buske C, Rawat VPS.Leuke­mia. 2021 Aug 30. doi: 10.1038/s41375-021-01390-3. Online ahead of print.PMID: 34462525

Single-​Agent Ibru­ti­nib for Rituximab-​Refractory Wal­den­ström's Macro­glo­bu­li­ne­mia: Final Ana­ly­sis of the Sub­study of the Phase III iNNO­VA­TETM Trial.

Trot­man J, Buske C, Tede­schi A, Matous JV, Mac­Do­nald D, Tam CS, Tour­nil­hac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-​Hisijara I, Dimo­pou­los MA. Clin Can­cer Res. 2021 Aug 11:clin­c­an­res.1497.2021. doi: 10.1158/1078-0432.CCR-21-1497. Online ahead of print. PMID: 34380643

A phase II study of the PI3K inhi­bi­tor cop­an­li­sib in com­bi­na­tion with the anti-​CD20 mono­clo­nal anti­body ritu­xi­mab for pati­ents with mar­gi­nal zone lym­phoma: treat­ment ratio­nale and pro­to­col design of the COUP-1 trial.

Gru­nen­berg A, Kai­ser LM, Woel­fle S, Schmelzle B, Viar­dot A, Möl­ler P, Barth TFE, Muche R, Drey­haupt J, Rade­rer M, Kie­se­wet­ter B, Buske C. BMC Can­cer. 2021 Jun 29;21(1):749. doi: 10.1186/s12885-021-08464-6. PMID: 34187401

Tar­ge­ting of CXCR4 by the Natu­rally Occur­ring CXCR4 Ant­ago­nist EPI-X4 in Wal­den­ström's Macro­glo­bu­li­ne­mia.

Kai­ser LM, Harms M, Sau­ter D, Rawat VPS, Glit­scher M, Hildt E, Tews D, Hun­ter Z, Münch J, Buske C. Can­cers (Basel). 2021 Feb 16;13(4):826. doi: 10.3390/can­cers13040826. PMID: 33669329

EHA/ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for the Manage­ment of Mali­gnant Lym­phoma: Recom­men­da­ti­ons for the Second Phase of the COVID-​19 Pan­de­mic.

Drey­ling M, Aurer I, Feder­ico M, Jer­ke­man M, Kers­ten MJ, Lin­ton K, Mey U, Tilly H, Buske C. Hemas­phere. 2021 Jan 27;5(2):e529. doi: 10.1097/HS9.0000000000000529. eColl­ec­tion 2021 Feb. PMID: 33880434

SARS-​CoV-2 infec­tion is asso­cia­ted with a pro-​thrombotic pla­te­let phe­no­type.

Bon­gio­vanni D, Klug M, Lazareva O, Weid­lich S, Biasi M, Ursu S, Warth S, Buske C, Lukas M, Spin­ner CD, Scheidt MV, Con­do­relli G, Baum­bach J, Laug­witz KL, List M, Bern­loch­ner I. Cell Death Dis. 2021 Jan 5;12(1):50. doi: 10.1038/s41419-020-03333-9. PMID: 33414384

TET1 pro­mo­tes growth of T-​cell acute lym­phob­lastic leuke­mia and can be ant­ago­ni­zed via PARP inhi­bi­tion.

Bame­zai S, Demir D, Pulik­kot­til AJ, Cic­ca­rone F, Fisch­bein E, Sinha A, Borga C, Te Kron­nie G, Meyer LH, Mohr F, Götze M, Cai­afa P, Deba­tin KM, Döh­ner K, Döh­ner H, González-​Menéndez I, Quintanilla-​Fend L, Herold T, Jere­mias I, Feuring-​Buske M, Buske C, Rawat VPS. Leuke­mia. 2021 Feb;35(2):389-403. doi: 10.1038/s41375-020-0864-3. Epub 2020 May 15. PMID: 32409690

CXCR4 in Wal­den­ström's Macro­glo­bu­li­nema: chan­ces and chal­lenges. Kai­ser LM, Hun­ter ZR, Treon SP, Buske C. Leuke­mia. 2021   Feb;35(2):333-345. doi: 10.1038/s41375-020-01102-3. Epub 2020 Dec 3. PMID: 33273682

The Onco­logy Data Net­work (ODN): Metho­do­logy, Chal­lenges, and Achie­vements.

Wool­more A, Arnold D, Blay JY, Buske C, Car­rato A, Ger­rit­sen W, Pee­ters M, Garcia-​Foncillas J, Kerr D. Onco­lo­gist. 2020 Oct;25(10):e1428-e1432. doi: 10.1634/the­on­co­lo­gist.2019-0855. Epub 2020 May 21. PMID: 32333623

Zanu­bru­ti­nib for the treat­ment of MYD88 wild-​type Wal­den­ström macro­glo­bu­li­ne­mia: a sub­study of the phase 3 ASPEN trial.

Dimo­pou­los M, Sanz RG, Lee HP, Trneny M, Varet­toni M, Opat S, D'Sa S, Owen RG, Cull G, Mul­ligan S, Czyz J, Cas­tillo JJ, Motta M, Sid­diqi T, Giro­nella Mesa M, Gra­nell Gor­ro­cha­te­gui M, Tal­au­likar D, Zin­zani PL, Askari E, Gro­si­cki S, Oriol A, Rule S, Kloczko J, Tede­schi A, Buske C, Leblond V, Trot­man J, Chan WY, Michel J, Schnei­der J, Tan Z, Cohen A, Huang J, Tam CS. Blood Adv. 2020 Dec 8;4(23):6009-6018. doi: 10.1182/bloo­dad­van­ces.2020003010. PMID: 33284944

A ran­do­mi­zed phase 3 trial of zanu­bru­ti­nib vs ibru­ti­nib in sym­pto­ma­tic Wal­den­ström macro­glo­bu­li­ne­mia: the ASPEN study.

Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marl­ton P, Wahlin BE, Sanz RG, McCar­thy H, Mul­ligan S, Tede­schi A, Cas­tillo JJ, Czyz J, Fernández de Lar­rea C, Belada D, Libby E, Matous JV, Motta M, Sid­diqi T, Tani M, Trneny M, Min­nema MC, Buske C, Leblond V, Trot­man J, Chan WY, Schnei­der J, Ro S, Cohen A, Huang J, Dimo­pou­los M. Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. PMID: 32731259

Con­sen­sus treat­ment recom­men­da­ti­ons from the tenth Inter­na­tio­nal Work­shop for Wal­den­ström Macro­glo­bu­li­nae­mia.

Cas­tillo JJ, Advani RH, Bra­na­gan AR, Buske C, Dimo­pou­los MA, D'Sa S, Kers­ten MJ, Leblond V, Min­nema MC, Owen RG, Palomba ML, Tal­au­likar D, Tede­schi A, Trot­man J, Varet­toni M, Vos JM, Treon SP, Kas­tri­tis E. Lan­cet Hae­ma­tol. 2020 Nov;7(11):e827-e837. doi: 10.1016/S2352-3026(20)30224-6. PMID: 33091356

Buske C. Bruton tyrosine-​kinase inhi­bi­tor on the rise: acala­b­ru­ti­nib in Wal­den­ström macro­glo­bu­li­ne­mia. Lan­cet Hae­ma­tol. 2020 Feb;7(2):e85-e86. doi: 10.1016/S2352-3026(19)30214-5. Epub 2019 Dec 19. PMID: 31866282.

Wool­more A, Arnold D, Blay JY, Buske C, Car­rato A, Ger­rit­sen W, Pee­ters M,Garcia-​Foncillas J, Kerr D. The Onco­logy Data Net­work (ODN): Metho­do­logy,  hal­lenges, and Achie­vements. Onco­lo­gist. 2020 Apr 25. doi:10.1634/the­on­co­lo­gist.2019-0855. Epub ahead of print. PMID: 32333623.

Heu­ser M, Ofran Y, Bois­sel N, Bru­net Mauri S, Crad­dock C, Jans­sen J,Wierz­bowska A, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Elec­tro­nic address: cli­ni­cal­gui­de­li­nes@esmo.org. Acute mye­loid leu­ka­e­mia in adult pati­ents: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2020 Mar 17:S0923-7534(20)36079-8. doi: 10.1016/j.annonc.2020.02.018. Epub ahead of print. PMID: 2171751.

Wool­more A, Arnold D, Blay JY, Buske C, Car­rato A, Ger­rit­sen W, Pee­ters M, Garcia-​Foncillas J, Kerr D. The Onco­logy Data Net­work (ODN): Metho­do­logy, Chal­lenges, and Achie­vements. Onco­lo­gist. 2020 Apr 25. doi: 10.1634/the­on­co­lo­gist.2019-0855. Epub ahead of print. PMID: 32333623.

Heu­ser M, Ofran Y, Bois­sel N, Bru­net Mauri S, Crad­dock C, Jans­sen J, Wierz­bowska A, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Elec­tro­nic address: cli­ni­cal­gui­de­li­nes@esmo.org. Acute mye­loid leu­ka­e­mia in adult pati­ents: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2020 Mar 17:S0923-7534(20)36079-8. doi: 10.1016/j.annonc.2020.02.018. Epub ahead of print. PMID: 32171751.

Bame­zai S, Demir D, Pulik­kot­til AJ, Cic­ca­rone F, Fisch­bein E, Sinha A, Borga C, Te Kron­nie G, Meyer LH, Mohr F, Götze M, Cai­afa P, Deba­tin KM, Döh­ner K, Döh­ner H, González-​Menéndez I, Quintanilla-​Fend L, Herold T, Jere­mias I, Feuring-​Buske M, Buske C, Rawat VPS. TET1 pro­mo­tes growth of T-​cell acute lym­phob­lastic leuke­mia and can be ant­ago­ni­zed via PARP inhi­bi­tion. Leuke­mia. 2020 May 15. doi: 10.1038/s41375-020-0864-3. Epub ahead of print. PMID: 32409690.

Kerr D, Arnold D, Blay JY, Buske C, Car­rato A, Ger­rit­sen W, Pee­ters M. The Onco­logy Data Net­work (ODN): A Col­la­bo­ra­tive European Data-​Sharing Plat­form to  Inform Can­cer Care. Onco­lo­gist. 2020 Jan;25(1):e1-e4. doi: 10.1634/the­on­co­lo­gist.2019-0337. Epub 2019 Sep 5. PMID: 31488619; PMCID: PMC6964115.

Vegi NM, Cha­kra­bortty S, Zegota MM, Kuan SL, Stum­per A, Rawat VPS, Sieste S, Buske C, Rau S, Weil T, Feuring-​Buske M. Soma­to­sta­tin recep­tor media­ted tar­ge­ting of acute mye­loid leuke­mia by pho­to­dy­na­mic metal com­ple­xes for light indu­ced apo­pto­sis. Sci Rep. 2020 Jan 15;10(1):371. doi: 10.1038/s41598-019-57172-6. PMID: 31941913; PMCID: PMC6962389.

Mayer S, Schmidtke-​Schrezenmeier G, Buske C, Rücker FG, Barth TFE, Möl­ler P, Mari­en­feld R. Res­cue of Non-​Informative Cir­cu­la­ting Tumor DNA to Moni­tor the Muta­tio­nal Land­s­cape in NSCLC. Can­cers (Basel). 2020 Jul 16;12(7):E1917. doi: 10.3390/can­cers12071917. PMID: 32708545.

Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marl­ton P, Wahlin BE, Garcia-​Sanz R, McCar­thy H, Mul­ligan S, Tede­schi A, Cas­tillo J, Czyz J, Fernández de Lar­rea C, Belada D, Libby E, Matous JV, Motta M, Sid­diqi T, Tani M, Trneny M, Min­nema MC, Buske C, Leblond V, Chan WY, Schnei­der JY, Ro S, Cohen A, Huang J, Dimo­pou­los MA. A RAN­DO­MI­ZED PHASE 3 TRIAL OF ZANU­BRU­TI­NIB VER­SUS IBRU­TI­NIB IN SYM­PTO­MA­TIC WAL­DEN­STRÖM MACRO­GLO­BU­LI­NE­MIA:THE ASPEN STUDY. Blood. 2020 Jul 30:blood.2020006844. doi: 10.1182/blood.2020006844. Epub ahead of print. PMID: 32731259.

Cas­tillo JJ, Itchaki G, Paludo J, Varet­toni M, Buske C, Eyre TA, Cha­vez JC, Shain KH, Issa S, Palomba ML, Pas­vol­sky O, Simpson D, Tal­au­likar D, Tam CS, Tede­schi A, Ansell SM, Nayak L, Treon SP. Ibru­ti­nib for the treat­ment of Bing-​Neel syn­drome: a mul­ti­cen­ter study. Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-​2018-10-879593. Epub 2018 Dec 6. PMID: 30523119.

Kas­tri­tis E, Leblond V, Dimo­pou­los MA, Kimby E, Sta­ber P, Kers­ten MJ, Tede­schi A, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Wal­den­ström's macro­glo­bu­li­nae­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. doi: 10.1093/annonc/mdy146. Erra­tum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. Erra­tum in: Ann Oncol. 2019 May 1;30(5):860-862. Erra­tum in: Ann Oncol. 2019 May;30(5):860-862. Erra­tum in: Ann Oncol. 2018 Oct;29 Suppl 4:iv270. PMID: 29982402.

Trot­man J, Bar­ring­ton SF, Belada D, Meig­nan M, MacE­wan R, Owen C, Ptáčník V, Rosta A, Fingerle-​Rowson GR, Zhu J, Niel­sen T, Sahin D, Hid­de­mann W, Mar­cus RE, Davies A; PET inves­ti­ga­tors from the GAL­LIUM study. Pro­gno­stic value of end-​of-induction PET response after first-​line immu­n­o­chemo­the­rapy for fol­li­cu­lar lym­phoma (GAL­LIUM): secon­dary ana­ly­sis of a ran­do­mi­sed, phase 3 trial. Lan­cet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8. Erra­tum in: Lan­cet Oncol. 2019 Apr 29;: PMID: 30309758.

Alta­mura S, Vegi NM, Hoppe PS, Schroe­der T, Aich­ler M, Walch A, Okre­gli­cka K, Hült­ner L, Schnei­der M, Ladi­nig C, Kuklik-​Roos C, Mys­li­wietz J, Janik D, Neff F, Rath­kolb B, de Ange­lis MTH, Buske C, Silva ARD, Mued­der K, Con­rad M, Ganz T Kopf M, Mucken­tha­ler MU, Born­kamm GW. Gluta­thione per­oxi­dase 4 and vit­amin E con­trol reti­cu­lo­cyte matu­ra­tion, stress ery­thro­poie­sis and iron homeo­sta­sis. Hae­ma­to­lo­gica. 2020 Apr;105(4):937-950. doi: 10.3324/hae­ma­tol.2018.212977. Epub 2019 Jun 27. PMID: 31248967; PMCID: PMC7109755.

Zucca E, Arcaini L, Buske C, John­son PW, Pon­zoni M, Rade­rer M, Ricardi U, Salar A, Sta­ma­to­pou­los K, Thieb­le­mont C, Wothers­poon A, Ladetto M; ESMO Gui­de­li­nes Com­mit­tee. Elec­tro­nic address: lini­cal­gui­de­li­nes@esmo.org. Mar­gi­nal zone lym­pho­mas: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4. PMID: 31912792.

Jurczak W, Długosz Dane­cka M, Buske C. Ritu­xi­mab bio­si­mi­lars for lym­phoma in Europe. Expert Opin Biol Ther. 2019 Oct;19(10):1045-1056. doi: 10.1080/14712598.2019.1665017. PMID: 31512535.

Gru­nen­berg A, Buske C. Ritu­xi­mab and ibru­ti­nib in the treat­ment of Wal­den­ström's macro­glo­bu­li­ne­mia. Future Oncol. 2019 Aug;15(23):2687-2697. doi: 10.2217/fon-2019-0154. Epub 2019 Jun 11. PMID: 31184501.

Bame­zai S, Buske C. Cut­ting Off Leu­ke­mo­ge­ne­sis: Hydra-​like Plasti­city of Mature Leuke­mic Cells. Cell Stem Cell. 2019 Aug 1;25(2):167-168. doi: 10.1016/j.stem.2019.07.005. PMID: 31374194.

Thoene S, Man­dal T, Vegi NM, Quintanilla-​Martinez L, Rös­ler R, Wiese S, Met­ze­ler KH, Herold T, Hafer­lach T, Döh­ner K, Döh­ner H, Schwarz­mül­ler L, Kling­mül­ler U, Buske C, Rawat VPS, Feuring-​Buske M. The ParaHox gene Cdx4 indu­ces acute ery­throid leuke­mia in mice. Blood Adv. 2019 Nov 26;3(22):3729-3739. doi: 10.1182/bloo­dad­van­ces.2019000761. PMID: 31770439; PMCID: PMC6880902.

Kas­tri­tis E, Leblond V, Dimo­pou­los MA, Kimby E, Sta­ber P, Kers­ten MJ, Tede­schi A, Buske C. Wal­den­ström's macro­glo­bu­li­nae­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. Erra­tum for: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. PMID: 30520968.

Gru­nen­berg A, Möl­ler P, Viar­dot A, Teleanu V, Eier­mann D, Buske C, Barth TF. Unusual trans­for­ma­tion of pri­mary ext­r­ano­dal mar­gi­nal zone B cell lym­phoma of the ute­rus into a nodal fol­li­cu­lar lym­phoma grade IIIB. Ann Hema­tol. 2019 Mar;98(3):797-799. doi: 10.1007/s00277-019-03598-x. Epub 2019 Jan 26. PMID: 30683997.

Gru­nen­berg A, Möl­ler P, Viar­dot A, Teleanu V, Eier­mann D, Buske C, Barth TF. Unusual trans­for­ma­tion of pri­mary ext­r­ano­dal mar­gi­nal zone B cell lym­phoma of the ute­rus into a nodal fol­li­cu­lar lym­phoma grade IIIB. Ann Hema­tol. 2019 Mar;98(3):797-799. doi: 10.1007/s00277-019-03598-x. Epub 2019 Jan 26. PMID: 30683997.

Kas­tri­tis E, Leblond V, Dimo­pou­los MA, Kimby E, Sta­ber P, Kers­ten MJ, Tede­schi A, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Wal­den­ström's macro­glo­bu­li­nae­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2018 Jul 5. doi: 10.1093/annonc/mdy146.

Gri­go­ryan A, Guidi N, Sen­ger K, Liehr T, Sol­ler K, Marka G, Voll­mer A, Mar­kaki Y, Leon­hardt H, Buske C, Lipka DB, Plass C, Zheng Y, Mulaw MA, Gei­ger H, Flo­rian MC. LaminA/C regu­la­tes epi­ge­ne­tic and chro­ma­tin archi­tec­ture chan­ges upon aging of hema­to­poie­tic stem cells. Genome Biol. 2018 Nov 7;19(1):189. doi:10.1186/s13059-018-1557-3. PMID: 30404662; PMCID: PMC6223039.

Hoch­haus A, Saus­sele S, Rosti G, Mahon FX, Jans­sen JJWM, Hjorth-​Hansen H,Rich­ter J, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Chro­nic mye­loid leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. Erra­tum for: Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. PMID: 30285223.

Buske C, Sadul­lah S, Kas­tri­tis E, Tede­schi A, García-​Sanz R, Bol­kun L, Leleu X, Wil­len­ba­cher W, Hájek R, Min­nema MC, Cheng M, Bilotti E, Graef T, Dimo­pou­los MA; European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia. Treat­ment and out­come pat­terns in European pati­ents with Wal­den­ström's macro­glo­bu­li­nae­mia: a large, obser­va­tio­nal, retro­spec­tive chart review. Lan­cet Hae­ma­tol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5.

Hut­chings M, Ladetto M, Buske C, de Nully Brown P, Fer­reri AJM, Pfreund­schuh M, Schmitz N, Balari AS, van Imhoff G, Walew­ski J; ESMO Lym­phoma Con­sen­sus Con­fe­rence Panel Mem­bers. ESMO Con­sen­sus Con­fe­rence on mali­gnant lym­phoma: manage­ment of 'ultra-​high-risk' pati­ents. Ann Oncol. 2018 Jun 19. doi: 10.1093/annonc/mdy167.

Tam CS, LeBlond V, Novotny W, Owen RG, Tede­schi A, Atwal S, Cohen A, Huang J, Buske C. A head-​to-head Phase III study com­pa­ring zanu­bru­ti­nib ver­sus ibru­ti­nib in pati­ents with Wal­den­ström macro­glo­bu­li­ne­mia. Future Oncol. 2018 Jun 5. doi: 10.2217/fon-2018-0163. 

Ogura M, San­cho JM, Cho SG, Naka­zawa H, Suzu­miya J, Tumyan G, Kim JS, Len­nard A, Mariz J, Ilyin N, Jurczak W, Lopez Mar­ti­nez A, Samoi­lova O, Zhav­rid E, Yañez Ruiz E, Trneny M, Popp­le­well L, Coif­fier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Effi­cacy, phar­ma­co­ki­ne­tics, and safety of the bio­si­mi­lar CT-P10 in com­pa­ri­son with ritu­xi­mab in pati­ents with pre­viously untrea­ted low-​tumour-burden fol­li­cu­lar lym­phoma: a ran­do­mi­sed, double-​blind, parallel-​group, phase 3 trial. Lan­cet Hae­ma­tol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1. PMID: 30389036.

Dimo­pou­los MA, Tede­schi A, Trot­man J, García-​Sanz R, Mac­do­nald D, Leblond V, Mahe B, Her­baux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shus­tik C, Kas­tri­tis E, Treon SP, Li J, Sal­man Z, Graef T, Buske C; iNNO­VATE Study Group and the European Con­sor­tium for Wal­den­ström’s Macro­glo­bu­li­ne­mia. Phase 3 Trial of Ibru­ti­nib plus Ritu­xi­mab in Wal­den­ström's Macro­glo­bu­li­ne­mia. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJ­Moa1802917. Epub 2018 Jun 1.

Kuchen­bauer F, Buske C. Revi­si­ting throm­bo­cy­to­pe­nia in acute pro­mye­lo­cy­tic leuke­mia. Leuke­mia. 2018 Jun;32(6):1477-1478. doi: 10.1038/s41375-018-0105-1. Epub 2018 Mar 23.

Buske C. In Reply.  Dtsch Arz­tebl Int. 2018 Mar 16;115(11):190. doi: 10.3238/arz­tebl.2018.0190b

Alig S, Juri­no­vic V, Pas­tore A, Bara­ria D, Häbe S, Hell­muth JC, Kridel R, Gas­coyne R, Schmidt C, Zöll­ner A, Buske C, Drey­ling M, Unter­halt M, Hid­de­mann W, Hos­ter E, Wei­gert O. Impact of age on gene­tics and treat­ment effi­cacy in fol­li­cu­lar lym­phoma. Hae­ma­to­lo­gica. 2018 Mar 15. pii: hae­ma­tol.2018.187773. doi: 10.3324/hae­ma­tol.2018.187773.

Jurczak W, Zin­zani PL, Gaidano G, Goy A, Pro­ven­cio M, Nagy Z, Robak T, Mad­docks K, Buske C, Ambark­hane S, Winder­lich M, Dirnberger-​Hertweck M, Korol­kie­wicz R, Blum KA. Phase IIa study of the CD19 anti­body MOR208 in pati­ents with relap­sed or refrac­tory B-​cell non-​Hodgkin's lym­phoma. Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.

Hoch­haus A, Saus­sele S, Rosti G, Mahon FX, Jans­sen JJWM, Hjorth-​Hansen H, Rich­ter J, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Chro­nic mye­loid leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv261. doi: 10.1093/annonc/mdy159. Erra­tum for: Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. PMID: 30285223.

Man­dal T, Beck M, Kirs­ten N, Lindén M, Buske C. Tar­ge­ting murine leuke­mic stem cells by anti­body func­tio­na­li­zed meso­porous silica nano­par­ticles. Sci Rep. 2018 Jan 17;8(1):989. doi: 10.1038/s41598-017-18932-4.

Buske C, Drey­ling M. [Mali­gnant B-​Cell Lym­phoma: Advan­ces in the The­rapy of Fol­li­cu­lar Lym­phoma and Mantle-​cell Lym­phoma]. Dtsch Med Wochen­schr. 2018 Jan;143(1):46-51. doi: 10.1055/s-0043-124004. Epub 2018 Jan 9. Ger­man. 

Her­zig JK, Bul­lin­ger L, Tas­do­gan A, Zim­mer­mann P, Schle­gel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dol­nik A, Schnei­der E, Kuchen­bauer F, Hei­del FH, Buske C, Döh­ner H, Döh­ner K, Gaid­zik VI. Pro­tein phos­phatase 4 regu­la­tory sub­u­nit 2 (PPP4R2) is recurrently dele­ted in acute mye­loid leuke­mia and requi­red for effi­ci­ent DNA dou­ble strand break repair. Onco­tar­get. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/onco­tar­get.21119. eColl­ec­tion 2017 Nov 10.

Schnei­der E, Staf­fas A, Röh­ner L, Malm­berg ED, Ashouri A, Kro­wiorz K, Pochert N, Mil­ler C, Wei SY, Ara­ba­nian L, Buske C, Döh­ner H, Bul­lin­ger L, Fogel­strand L, Heu­ser M, Döh­ner K, Xiang P, Rusch­mann J, Petriv OI, Heravi-​Moussavi A, Han­sen CL, Hirst M, Hum­phries RK, Rouhi A, Palm­qvist L, Kuchen­bauer F. Micro-​ribonucleic acid-155 is a direct tar­get of Meis1, but not a dri­ver in acute mye­loid leuke­mia. Hae­ma­to­lo­gica. 2018 Feb;103(2):246-255. doi: 10.3324/hae­ma­tol.2017.177485. Epub 2017 Dec 7.

Buske C, Hut­chings M, Ladetto M, Goede V, Mey U, Sou­bey­ran P, Spina M, Stau­der R, Trnený M, Wed­ding U, Fields P; ESMO Lym­phoma Con­sen­sus Con­fe­rence Panel Mem­bers . ESMO Con­sen­sus Con­fe­rence on mali­gnant lym­phoma: gene­ral per­spec­ti­ves and recom­men­da­ti­ons for the cli­ni­cal manage­ment of the elderly pati­ent with mali­gnant lym­phoma. Ann Oncol. 2018 Mar 1;29(3):544-562. doi: 0.1093/annonc/mdx413.

Buske C. Alky­la­ting Agents in the Treat­ment of Wal­den­ström Macro­glo­bu­li­ne­mia. Hema­tol Oncol Clin North Am. 2018 Oct;32(5):821-827. doi: 10.1016/j.hoc.2018.05.009. Epub 2018 Jul 25. PMID: 30190020.

Dimo­pou­los MA, Sal­man Z, Buske C. Ibru­ti­nib and Ritu­xi­mab in Wal­den­ström's Macro­glo­bu­li­ne­mia. N Engl J Med. 2018 Nov 15;379(20):1975-1976. doi: 10.1056/NEJMc1809505. PMID: 30428288.

Ren­te­ria R, Buske TR, Mor­ri­sett RA. Long-​term subregion-​specific enco­ding of enhan­ced etha­nol intake by D1DR medium spiny neu­rons of the nucleus accum­bens. Addict Biol. 2018 Mar;23(2):689-698. doi: 10.1111/adb.12526. Epub 2017 Jun 28. PMID: 28656742; PMCID: PMC6264790.

Ladetto M, Buske C, Hut­chings M, Drey­ling M, Gaidano G, Le Gouill S, Lumi­nari S, Pott C, Zamò A, Zucca E; ESMO Lym­phoma Con­sen­sus Con­fe­rence Panel Mem­bers. ESMO con­sen­sus con­fe­rence on mali­gnant lym­phoma: gene­ral per­spec­ti­ves and recom­men­da­ti­ons for pro­gno­stic tools in mature B-​cell lym­pho­mas and chro­nic lym­pho­cy­tic leu­ka­e­mia. Ann Oncol. 2018 Feb 1;29(2):525. doi: 10.1093/annonc/mdx061. Erra­tum for: Ann Oncol. 2016 Dec;27(12):2149-2160. PMID: 28368466.

Kas­tri­tis E, Leblond V, Dimo­pou­los MA, Kimby E, Sta­ber P, Kers­ten MJ, Tede­schi A, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Wal­den­ström's macro­glo­bu­li­nae­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. doi: 10.1093/annonc/mdy322. Erra­tum for: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50. PMID: 30285219.

Braess J, Amler S, Kreu­zer KA, Spie­ker­mann K, Lin­de­mann HW, Leng­fel­der E, Grae­ven U, Staib P, Lud­wig WD, Bier­sack H, Ko YD, Uppen­kamp MJ, De Wit M, Kors­ten S, Peceny R, Gaska T, Schiel X, Beh­rin­ger DM, Kiehl MG, Zinn­grebe B, Mecken­stock G, Roe­mer E, Med­gen­berg D, Spaeth-​Schwalbe E, Mas­sen­keil G, Hin­dahl H, Schwerdt­fe­ger R, Trenn G, Sauer­land C, Koch R, Lablans M, Fal­dum A, Gör­lich D, Boh­l­an­der SK, Schnei­der S, Dufour A, Buske C, Fiegl M, Sub­klewe M, Braess B, Unter­halt M, Baum­gart­ner A, Wör­mann B, Bee­len D, Hid­de­mann W; AML-​CG. Sequen­tial high-​dose cyt­ara­bine and mit­ox­an­trone (S-HAM) ver­sus stan­dard dou­ble induc­tion in acute mye­loid leukemia-​a phase 3 study. Leuke­mia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1. PMID: 30275528; PMCID: PMC6286323.

Hoch­haus A, Saus­sele S, Rosti G, Mahon FX, Jans­sen JJWM, Hjorth-​Hansen H, Rich­ter J, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Cor­rec­tions to "Chro­nic mye­loid leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up". Ann Oncol. 2018 Oct;29 Suppl 4:iv261. doi: 10.1093/annonc/mdy159. Epub 2020 Jan 7. Erra­tum for: Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. PMID: 32169232.

Lang­gart­ner D, Füchsl AM, Kai­ser LM, Meier T, Foertsch S, Buske C, Reber SO, Mulaw MA. Bio­mar­kers for clas­si­fi­ca­tion and class pre­dic­tion of stress in a murine model of chro­nic sub­or­di­na­tion stress. PLoS One. 2018 Sep 5;13(9):e0202471. doi: 10.1371/jour­nal.pone.0202471. PMID: 30183738; PMCID: PMC6124755.

Hoch­haus A, Saus­sele S, Rosti G, Mahon FX, Jans­sen JJWM, Hjorth-​Hansen H, Rich­ter J, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Chro­nic mye­loid leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51.  

Kim WS, Buske C, Ogura M, Jurczak W, San­cho JM, Zhav­rid E, Kim JS, Hernández-​Rivas JÁ, Prok­ha­rau A, Vasi­lica M, Nagar­kar R, Osma­nov D, Kwak LW, Lee SJ, Lee SY, Bae YJ, Coif­fier B. Effi­cacy, phar­ma­co­ki­ne­tics, and safety of the bio­si­mi­lar CT-P10 com­pa­red with ritu­xi­mab in pati­ents with pre­viously untrea­ted advanced-​stage fol­li­cu­lar lym­phoma: a ran­do­mi­sed, double-​blind, parallel-​group, non-​inferiority phase 3 trial. Lan­cet Hae­ma­tol. 2017 Aug;4(8):e362-e373. doi: 10.1016/S2352-3026(17)30120-5. Epub 2017 Jul 14. PMID: 28712940

Beck M, Man­dal T, Buske C, Lindén M. Serum Pro­tein Adsorp­tion Enhan­ces Active Leuke­mia Stem Cell Tar­ge­ting of Meso­porous Silica Nano­par­ticles. ACS Appl Mater Inter­faces. 2017 Jun 7;9(22):18566-18574. doi: 10.1021/acsami.7b04742. Epub 2017 May 25. PMID: 28525262

Buske C, Ogura M, Kwon HC, Yoon SW. An intro­duc­tion to bio­si­mi­lar can­cer the­ra­peu­tics: defi­ni­ti­ons, ratio­nale for deve­lo­p­ment and regu­la­tory requi­re­ments. Future Oncol. 2017 May;13(15s):5-16. doi: 10.2217/fon-2017-0153. PMID: 28482702

Moreau P, San Miguel J, Son­ne­veld P, Mateos MV, Zama­gni E, Avet-​Loiseau H, Hajek R, Dimo­pou­los MA, Lud­wig H, Ein­sele H, Zweegman S, Facon T, Cavo M, Ter­pos E, Gold­schmidt H, Attal M, Buske C, ESMO Gui­de­li­nes Com­mit­tee. Mul­ti­ple mye­loma: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up†. Ann Oncol. 2017 Apr 27. doi: 10.1093/annonc/mdx096. [Epub ahead of print] No abs­tract availa­ble. PMID: 28453614

Cha­kra­bortty S, Agra­walla BK, Stum­per A, Vegi NM, Fischer S, Rei­chardt C, Kög­ler M, Diet­zek B, Feuring-​Buske M, BuskeC, Rau S, Weil T. Mito­chon­dria Tar­ge­ted Protein-​Ruthenium Pho­to­sen­si­ti­zer for Effi­ci­ent Pho­to­dy­na­mic Appli­ca­ti­ons. J Am Chem Soc. 2017 Feb 15;139(6):2512-2519. doi: 10.1021/jacs.6b13399. Epub 2017 Feb 7. PMID: 28097863

Dimo­pou­los MA, Trot­man J, Tede­schi A, Matous JV, Mac­do­nald D, Tam C, Tour­nil­hac O, Ma S, Oriol A, Heff­ner LT, Shus­tik C, García-​Sanz R, Cor­nell RF, de Lar­rea CF, Cas­tillo JJ, Gra­nell M, Kyrt­so­nis MC, Leblond V, Symeo­ni­dis A, Kas­tri­tis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNO­VATE Study Group and the European Con­sor­tium for Wal­den­ström's Macro­glo­bu­li­ne­mia. Ibru­ti­nib for pati­ents with rituximab-​refractory Wal­den­ström's macro­glo­bu­li­nae­mia (iNNO­VATE): an open-​label sub­study of an inter­na­tio­nal, mul­ti­centre, phase 3 trial.https://www.ncbi.nlm.nih.gov/pub­med/27956157 Lan­cet Oncol. 2016 Dec 9. pii: S1470-2045(16)30632-5. doi: 10.1016/S1470-2045(16)30632-5.

Kro­wiorz K, Rusch­mann J, Lai C, Ngom M, Maet­zig T, Mar­tins V, Schef­fold A, Schnei­der E, Pochert N, Mil­ler C, Palm­qvist L, Staf­fas A, Mulaw M, Bohl SR, Buske C, Heu­ser M, Kraus J, O'Neill K, Han­sen CL, Petriv OI, Kest­ler H, Döh­ner H, Bul­lin­ger L, Döh­ner K, Hum­phries RK, Rouhi A, Kuchen­bauer F. MiR-139-5p is a potent tumor sup­pres­sor in adult acute mye­loid leuke­mia. Blood Can­cer J. 2016 Dec 9;6(12):e508. doi: 10.1038/bcj.2016.110.

Ng SW, Mit­chell A, Ken­nedy JA, Chen WC, McLeod J, Ibra­hi­mova N, Arruda A, Popescu A, Gupta V, Schim­mer AD, Schuh AC, Yee KW, Bul­lin­ger L, Herold T, Gör­lich D, Büch­ner T, Hid­de­mann W, Ber­del WE, Wör­mann B, Cheok M, Preud­homme C, Dom­bret H, Met­ze­ler K, Buske C, Löwen­berg B, Valk PJ, Zand­s­tra PW, Min­den MD, Dick JE, Wang JC. A 17-gene stem­ness score for rapid deter­mi­na­tion of risk in acute leu­ka­e­mia. Nature. 2016 Dec 7. doi: 10.1038/nature20598.

Buske C. Ofa­tu­mu­mab: ano­ther way to tar­get CD20 in Wal­den­ström's macro­glo­bu­li­nae­mia? Lan­cet Hae­ma­tol. 2016 Nov 30. pii: S2352-3026(16)30163-6. doi: 10.1016/S2352-3026(16)30163-6.

Gent­ner E, Vegi NM, Mulaw MA, Man­dal T, Bame­zai S, Claus R, Tas­do­gan A, Quintanilla-​Martinez L, Gru­nen­berg A, Döh­ner K, Döh­ner H, Bul­lin­ger L, Hafer­lach T, Buske C, Rawat VP, Feuring-​Buske M. VENTX indu­ces expan­sion of pri­mi­tive ery­throid cells and con­tri­bu­tes to the deve­lo­p­ment of acute mye­loid leuke­mia in mice. Onco­tar­get. 2016 Nov 24. doi: 10.18632/onco­tar­get.13563.

Cusan M, Vegi NM, Mulaw MA, Bame­zai S, Kai­ser LM, Desh­pande AJ, Greif PA, Quintanilla-​Fend L, Göll­ner S, Müller-​Tidow C, Hum­phries KR, Arm­strong SA, Hid­de­mann W, Feuring-​Buske M, Buske C. Con­trol­led stem cell ampli­fi­ca­tion by HOXB4 depends on its uni­que proline-​rich region near the N-​terminus. Blood. 2016 Nov 8. pii: blood-​2016-04-706978.

Bogen A, Buske C, Hid­de­mann W, Boh­l­an­der SK, Christ O. Varia­ble alde­hyde dehy­dro­genase acti­vity and effects on che­mo­sen­si­ti­vity of pri­mi­tive human leuke­mic cells. Exp Hema­tol. 2016 Nov 5. pii: S0301-472X(16)30695-6. doi: 10.1016/j.exphem.2016.10.012.

Ladetto M, Buske C, Hut­chings M, Drey­ling M, Gaidano G, Le Gouill S, Lumi­nari S, Pott C, Zamò A, Zucca E; ESMO Lym­phoma Con­sen­sus Con­fe­rence Panel Mem­bers.. ESMO con­sen­sus con­fe­rence on mali­gnant lym­phoma: gene­ral per­spec­ti­ves and recom­men­da­ti­ons for pro­gno­stic tools in mature B-​cell lym­pho­mas and chro­nic lym­pho­cy­tic leu­ka­e­mia. Ann Oncol. 2016 Oct 4. pii: mdw419.

Eich­horst B, Robak T, Monts­er­rat E, Ghia P, Hill­men P, Hal­lek M, Buske C; ESMO Gui­de­li­nes Com­mit­tee..appen­dix 6: Chro­nic lym­pho­cy­tic leu­ka­e­mia: eUp­date published online Sep­tem­ber 2016 (http://www.esmo.org/Gui­de­li­nes/Haematological-​Malignancies). Ann Oncol. 2016 Sep;27(suppl 5):v143-v144.

Leblond V, Kas­tri­tis E, Advani R, Ansell SM, Buske C, Cas­tillo JJ, García-​Sanz R, Gertz M, Kimby E, Kyria­kou C, Mer­lini G, Min­nema MC, Morel P, Morra E, Rum­mel M, Wecha­le­kar A, Pat­ter­son CJ, Treon SP, Dimo­pou­los MA. Treat­ment recom­men­da­ti­ons for Wal­den­ström macro­glo­bu­li­ne­mia from the Eighth Inter­na­tio­nal Work­shop on WM. Blood 2016 Jul 18. pii: blood-​2016-04-711234.

Vegi NM, Klapp­a­cher J, Oswald F, Mulaw MA, Man­doli A, Thiel VN, Bame­zai S, Feder K, Mar­tens JH, Rawat VP, Man­dal T, Quintanilla-​Martinez L, Spie­ker­mann K, Hid­de­mann W, Döh­ner K, Döh­ner H, Stun­nen­berg HG, Feuring-​Buske M, Buske C. MEIS2 Is an Onco­ge­nic Part­ner in AML1-​ETO-Positive AML. Cell Rep. 2016 Jul 12;16(2):498-507.

Daria D, Kirs­ten N, Muranyi A, Mulaw M, Ihme S, Kech­ter A, Holl­na­gel M, Bul­lin­ger L, Döh­ner K, Döh­ner H, Feuring-​Buske M, Buske C. GPR56 con­tri­bu­tes to the deve­lo­p­ment of acute mye­loid leuke­mia in mice. Leuke­mia 2016 Aug;30(8):1734-41.

Daria D, Kirs­ten N, Muranyi A, Mulaw M, Ihme S, Kech­ter A, Bul­lin­ger L, Döh­ner K, Döh­ner H, Feuring-​Buske M, Buske C. GPR56 con­tri­bu­tes to the deve­lo­p­ment of acute mye­loid leuke­mia in mice. Leuke­mia 2016; Apr 11. doi: 10.1038/leu.2016.76.

Hoel­zer D, Bassan R, Dom­bret H, Fiel­ding A, Ribera JM, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Acute lym­phob­lastic leu­ka­e­mia in adult pati­ents: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol  2016; Apr 7. pii: mdw025.

Gru­nen­berg A, Buske C. New deve­lo­p­ments in Wal­den­ström's macro­glo­bu­li­ne­mia. Dtsch Med Wochen­schr 2016; Feb;141(3):170-2. doi: 10.1055/s-0041-107960.

Schmid F, Schmid M, Müs­sel C, Sträng JE, Buske C, Bul­lin­ger L, Kraus JM, Kest­ler HA. GiANT: gene set uncer­tainty in enrich­ment ana­ly­sis. Bio­in­for­ma­tics 2016; Feb 1. pii: btw030. 

Gru­nen­berg A, Buske C. Wal­den­ström's macro­glo­bu­li­ne­mia : Cur­rent deve­lo­p­ments in dia­gno­stics and the­rapy. Inter­nist(Berl) 2016; Mar;57(3):238-44. doi: 10.1007/s00108-015-0005-7.

Engert A, Bal­du­ini C, Brand A, Coif­fier B, Cor­don­nier C, Döh­ner H, de Wit TD, Eichin­ger S, Fibbe W, Green T, de Haas F, Iolas­con A, Jaf­fredo T, Rodeg­hiero F, Sal­les G, Schu­ringa JJ; EHA Road­map for European Hema­to­logy Rese­arch. The European Hema­to­logy Asso­cia­tion Road­map for European Hema­to­logy Rese­arch: a con­sen­sus docu­ment. Hae­ma­to­lo­gica2016; Feb;101(2):115-208. doi: 10.3324/hae­ma­tol.2015.136739.

Schnei­der D, Dühren-​von Min­den M, Alk­ha­tib A, Setz C, van Ber­gen CA, Benkißer-​Petersen M, Wil­helm I, Vill­rin­ger S, Kry­sov S, Pack­ham G, Zir­lik K, Römer W, Buske C, Ste­ven­son FK, Veel­ken H, Jumaa H. Lec­tins from oppor­tu­ni­stic bac­te­ria inter­act with acqui­red variable-​region glycans of sur­face immu­n­o­glo­bu­lin in fol­li­cu­lar lym­phoma. Blood 2015; 125(21): 3287-3296.

Hess G, Kel­ler U, Scholz CW, Witzens-​Harig M, Atta J, Buske C, Kir­schey S, Ruckes C, Med­ler C, van Oordt C, Klap­per W, Theo­bald M, Drey­ling M. Safety and effi­cacy of Tem­si­ro­li­mus in com­bi­na­tion with Ben­da­mus­tine and Ritu­xi­mab in relap­sed man­tle cell and fol­li­cu­lar lym­phoma. Leuke­mia 2015; 29(8): 1695-1701.

Gent­ner B, Pochert N, Rouhi A, Boc­calatte F, Plati T, Berg T, Sun SM, Mah SM, Mirkovic-​Hösle M, Rusch­mann J, Muranyi A, Lei­er­se­der S, Argi­ro­pou­los B, Star­czy­now­ski DT, Kar­san A, Heu­ser M, Hogge D, Camargo FD, Engel­hardt S, Döh­ner H, Buske C, Jongen-​Lavrencic M, Nal­dini L, Hum­phries RK, Kuchen­bauer F. MicroRNA-​223 dose levels fine tune pro­li­fe­ra­tion and dif­fe­ren­tia­tion in human cord blood pro­ge­ni­tors and acute mye­loid leuke­mia. Exp Hema­tol 2015; pii: S0301-472X(15)00511-1.

Van­nuc­chi AM, Bar­bui T, Cer­van­tes F, Har­ri­son C, Kilad­jian JJ, Krö­ger N, Thiele J, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Phil­adel­phia chromoseome-​negative chro­nic mye­lo­pro­li­fe­ra­tive neo­plasms: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol 2015; Suppl. 5: V85-V99.

Robak T, Matu­tes E, Catovsky D, Zin­zani PL, Buske C; ESMO Gui­de­li­nes Com­mit­tee. Hairy cell leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol 2015; Suppl. 5: v100-v107.

Eich­horst B, Robak T, Monts­er­rat E, Ghia P, Hill­men P, Hal­lek M, Buske C, ESMO Gui­de­li­nes Com­mit­tee. Chro­nic lym­pho­cy­tic leu­ka­e­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol 2015; Suppl. 5: v78-v84.

Buske C, Sey­mour J. Immu­n­o­chemo­the­rapy in Wal­den­ström macro­glo­bu­li­ne­mia - still the back­bone of treat­ment. Leuk Lym­phoma. 2015 Jun 9: 1-6.

Schnei­der V, Zhang L, Rojew­ski M, Fekete N, Schre­zen­meier H, Erle A, Bul­lin­ger L, Hof­mann s, Götz M, Döh­ner K, Ihme S, Döher H, Buske C, Feuring-​Buske M, Grei­ner J. Leuke­mic pro­ge­ni­tor cells are suscep­ti­ble to tar­ge­ting by sti­mu­la­ted cyto­to­xic T cells against immu­n­o­ge­nic leukemia-​associated anti­gens. Int J Can­cer 2015, Apr 24. doi: 10.1002/ijc.29583.

2014

Buske C. Towards a chemotherapy-​free approach in indo­lent lym­phoma. Lan­cet Oncol. 2014 Nov;15(12):1281-2.

Fen­aux P, Haase D, Sanz GF, San­tini V, Buske C; ESMO Gui­de­li­nes Work­ing Group. Mye­lo­dys­plastic syn­dro­mes: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2014 Sep;25 Suppl 3:iii57-69. 

Edmaier KE, Stahnke K, Vegi N, Mulaw M, Ihme S, Schef­fold A, Rudolph KL, Buske C. Expres­sion of the lym­phoid enhan­cer fac­tor 1 (Lef-1) is requi­red for nor­mal hema­to­poie­tic stem and pro­ge­ni­tor cell func­tion. Leuke­mia. 2014 Jan;28(1):227-30. 

Pas­tore F, Dufour A, Bent­haus T, Met­ze­ler KH, Maharry KS, Schnei­der S, Ksi­en­zyk B, Mel­lert G, Zell­meier E, Kaka­dia PM, Unter­halt M, Feuring-​Buske M, Buske C, Braess J, Sauer­land MC, Hein­ecke A, Krug U, Ber­del WE, Buech­ner T, Woer­mann B, Hid­de­mann W, Boh­l­an­der SK, Mar­cucci G, Spie­ker­mann K, Bloom­field CD, Hos­ter E; Com­bi­ned Mole­cu­lar and Cli­ni­cal Pro­gno­stic Index for Relapse and Sur­vi­val in Cyto­ge­ne­ti­cally Nor­mal Acute Mye­loid Leuke­mia. J Clin Oncol. 2014 Apr 7.

CR Stad­ler, N Vegi, MA Mulaw, KE Edmaier, VPS Rawat, A Dol­nik, L Bul­lin­ger, B Heil­meier, L Quintanilla-​Fend, K Spie­ker­mann, W Hid­de­mann, K Döh­ner, H Döh­ner, M Feuring-​Buske, C Buske; The leu­ke­mo­ge­ni­city of Hoxa9 depends on alter­na­tive spli­cing. Leuke­mia 2014  AMBER13-LEU-1614R

2013

Buske C, Leblond V, Dimo­pou­los M, Kimby E, Jäger U, Drey­ling M; ESMO Gui­de­li­nes Work­ing Group, Wal­den­strom's macro­glo­bu­li­nae­mia: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2013 Oct;24 Suppl 6:vi155-vi159.

Fey MF, Buske C; ESMO Gui­de­li­nes Work­ing Group. Acute mye­lob­lastic leu­ka­e­mias in adult pati­ents: ESMO Cli­ni­cal Prac­tice Gui­de­li­nes for dia­gno­sis, treat­ment and follow-​up. Ann Oncol. 2013 Oct;24 Suppl 6:vi138-vi143.

Herold T, Mulaw MA, Juri­no­vic V, Sei­ler T, Met­ze­ler KH, Dufour A, Schnei­der S, Kaka­dia PM, Spie­ker­mann K, Mans­mann U, Hid­de­mann W, Buske C, Drey­ling M, Boh­l­an­der SK. High expres­sion of MZB1 pre­dicts adverse pro­gno­sis in chro­nic lym­pho­cy­tic leuke­mia, fol­li­cu­lar lym­phoma and dif­fuse large B-​cell lym­phoma and is asso­cia­ted with a uni­que gene expres­sion signa­ture. Leuk Lym­phoma. 2013 Aug;54(8):1652-7. 

Wu Y, Ihme S, Feuring-​Buske M, Kuan SL, Eisele K, Lamla M, Wang Y, Buske C, Weil T. A Core-​Shell Albu­min Copo­ly­mer Nano­trans­por­ter for High Capa­city Loading and Two-​Step Release of Doxo­ru­bi­cin with Enhan­ced Anti-​Leukemia Acti­vity. Adv Heal­thc Mater. 2013 Jun;2(6):884-94. 

Chen L, Desh­pande A, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Dai­gle SR, Richon VM, Pol­lock RM, Arm­strong SA. Abro­ga­tion of MLL-​AF10 and CALM-​AF10 media­ted trans­for­ma­tion through gene­tic inac­ti­va­tion or phar­ma­co­lo­gi­cal inhi­bi­tion of the H3K79 methyl­trans­fer­ase Dot1l. Leuke­mia. 2013 Apr;27(4):813-22. 

Buske C. & Leblond V. How I manage to treat Wal­den­strom’s macro­glo­bu­li­ne­mia. Leuke­mia. 2013 Apr;27(4):762-72.

Gra­se­dieck S, Sor­ren­tino A, Lan­ger C, Buske C, Döh­ner H, Mer­tens D, Kuchen­bauer F. Cir­cu­la­ting microR­NAs in hema­to­lo­gi­cal disea­ses: prin­ci­ples, chal­lenges and per­spec­ti­ves. Blood 2013 Jun 20;121(25):4977-84.

Diff­ner E, Beck D, Gud­gin E, Thoms J, Kne­ze­vic K, Pri­dans C, Fos­ter S, Goode D, Khong Lim W, Boe­len L, Met­ze­ler K, Mick­lem G, Boh­l­an­der S, Buske C, Bur­nett A, Otters­bach K, Vas­si­liou G, Oli­vier J, Wong J, Gott­gens B, Huntly B, Pimanda JE. Acti­vity of a hep­tad of tran­scrip­tion fac­tors is asso­cia­ted with stem cell pro­grams and cli­ni­cal out­come in acute mye­loid leu­ka­e­mia. Blood. 2013 Mar 21;121(12):2289-300. 

2012

Lan­ger C, Rücker FG, Buske C, Döh­ner H, Kuchen­bauer F. Tar­ge­ted the­ra­pies through microR­NAs: pulp or fic­tion? Ther Adv Hema­tol. 2012 Apr;3(2):97-104.

Buske C, Herold M, Wil­len­ba­cher W, Drey­ling M. Fol­li­ku­lä­res Lym­phom. Onkopedia-​DGHO, Mai 2012.

Bame­zai S, Rawat VP, Buske C. The Piwi - piRNA Axis: Pivo­tal Beyond Trans­po­son Silen­cing. Stem Cells. 2012, 12: 2603-2611.

Witzens-​Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Rei­ser M, Pott C, Pelz H, La Rosée P, Kirch­ner H, Kiewe P, Kel­ler U, Buske C, Viar­dot A, Drey­ling M. Ann Hema­tol. 2012, 11: 1765-1772.

Met­ze­ler KH, Heil­meier B, Edmaier KE, Rawat VPS, Dufour A, Doeh­ner K, Feuring-​Buske M, Braess J, Spie­ker­mann K, Buchener T, Sauer­land MC, Doeh­ner H, Hid­de­mann W, Boh­l­an­der SK, Schlenk RF, Bul­lin­ger L, Buske C. High expres­sion of lym­phoid enhancer-​binding factor-​1 (LEF1) is a novel favorable pro­gno­stic fac­tor in cyto­ge­ne­ti­cally nor­mal acute mye­loid leuke­mia. Blood 2012; 120 (10): 2118 - 2126.

Mulaw MA, Krause AJ, Desh­pande AJ, Krause LF, Rouhi A, La Starza R, Bork­hardt A, Buske C, Mecucci C, Lud­wig WD, Lot­taz C, Boh­l­an­der SK. CALM/AF10-​positive leuke­mias show upre­gu­la­tion of genes invol­ved in chro­ma­tin assem­bly and DNA repair proces­ses and of genes adja­cent to the break­point at 10p12. Leuke­mia. 2012 May; 26(5): 1012 - 1019.

Mantelzell-​ Lym­phom. Drey­ling M, Herold M, Drach J, Rum­mel M, Buske C. Onkopedia-​DGHO, März 2012.

Schnei­der F, Hos­ter E, Unter­halt M, Schnei­der S, Dufour A, Bent­haus T, Mel­lert G, Zell­meier E, Kaka­dia PM, Boh­l­an­der SK, Feuring-​Buske M, Buske C, Braess J, Hein­ecke A, Sauer­land MC, Ber­del WE, Buech­ner T, Woer­mann BJ, Hid­de­mann W, Spie­ker­mann K. The FLT3ITD level has a high pro­gno­stic impact in NPM1 muta­ted, but not NPM1 unmuta­ted AML with a nor­mal karyo­type. Blood. 2012 119: 4383-4386.

Rawat VP, Hum­phries RK, Buske C. Beyond HOX: the role of ParaHOX genes in nor­mal and mali­gnannt hemat­poie­sis. Blood. 2012 120(3): 519-527.

Gra­se­dieck S, Sch­öler N, Bom­mer M, Niess JH, Tumani H, Rouhi A, Blo­eh­dorn J, Lie­bisch P, Mer­tens D, Döh­ner H, Buske C, Lan­ger C, Kuchen­bauer F. Impact of serum sto­rage con­di­ti­ons on microRNA sta­bi­lity. Leuke­mia. 2012, 26 (11): 2414-2416. 

Schnei­der F, Hos­ter E, Schnei­der S, Dufour A, Bent­haus T, Kaka­dia PM, Boh­l­an­der SK, Braess J, Hein­ecke A, Sauer­land MC, Bergel WE, Buech­ner T, Woer­mann BJ, Feuring-​Buske M, Buske C, Creut­zig U, Thiede C, Zwaan MC, van den Heuvel-​Eibrink MM, Rein­hardt D, Hid­de­mann W, Spie­ker­mann K. Age-​dependent fre­quen­cies of NPM1 muta­ti­ons and FLT3-ITD in pati­ents with nor­mal kario­type AML (NK-​AML). Ann Hema­tol 2012; 91: 9-18.

Azim­za­deh O, Scherthan H, Yen­tra­palli R, Bar­jak­ta­ro­vic Z, Uef­fing M, Con­rad M, Neff F, Calzada-​Wack J, Aubele M, Buske C, Atkin­son MJ, Hauck SM, Tapio S. Label-​free pro­tein pro­fi­ling of for­ma­lin fixed paraffin-​embedded (FFPE) heart tis­sue reveals imme­diate mito­chon­drial impair­ment after ionis­ing radia­tion. J Pro­teo­mics. 2012 Apr 18;75(8):2384-95.

2011

Mohr F, Döh­ner K, Buske C, et al. TET genes: New play­ers in DNA deme­thy­la­tion and important deter­mi­nants for stem­ness. Exp Hema­tol 2011; 39: 272-281.

Eppert K, Takenaka K, Lech­man ER, et al. Stem cell gene expres­sion pro­grams influ­ence cli­ni­cal out­come in human leuke­mia. Nature Medi­cine 2011; 17: 1086-1093.

Kuchen­bauer F, Mah SM, Heu­ser M, et al. Com­pre­hen­sive ana­ly­sis of mamma­lian miRNA* spe­cies and their role in mye­loid cells. Blood 2011; 118(12): 3350-3358.

Rouhi A, Buske C. Stem cells and beyond: report on the 40th Annual Sci­en­ti­fic Mee­ting of the Inter­na­tio­nal Society of Expe­ri­men­tal Hema­to­logy. Expert Rev Hema­tol 2011; 4(6): 591-592.

Desh­pande AJ, Rouhi A, Lin Y, et al. The clath­rin bin­ding domain of CALM and OM-LZ domain of AF10 are suf­fi­ci­ent to induce acute mye­loid leuke­mia in mice. Leuke­mia 2011; 25(11): 1718-1727.

Azim­za­deh O, Scherthan H, Sario­glu H, Bar­jak­ta­ro­vic Z, Con­rad M, Vogt A, Calzada-​Wack J, Neff F, Aubele M, Buske C, Atkin­son MJ, Tapio S. Rapid pro­teo­mic remo­de­ling of car­diac tis­sue cau­sed by total body ioni­zing radia­tion. J Pro­teo­mics 2011 11: 3299-3311.

Herold T, Juri­no­vic V, Mulaw M, et al. Expres­sion ana­ly­sis of genes loca­ted in the mini­mally dele­ted regi­ons of 13q14 and 11q22-23 in chro­nic lym­pho­cy­tic leukemia-​unexpected expers­sion pat­tern of the RHO GTPase acti­va­tor ARHGAP20.  Genes Chro­mo­so­mes Cen­ter 2011; 50: 546-558.

Herold T, Juri­no­vic V, Met­ze­ler KH, et al. An 8 gene expres­sion signa­ture for the pre­dic­tion of sur­vi­val and time to treat­ment in chro­nic lym­pho­cy­tic leuke­mia. Leuke­mia 2011; 25: 1639-1645.

2010

Rawat VP, Arseni N, Ahmed F, et al. The vent-​like home­obox gene VENTX pro­mo­tes human mye­loid dif­fe­ren­tia­tion and is highly expres­sed in acute mye­loid leuke­mia. Proc Natl Acad Sci U S A. 2010; 107(39): 16946-19851.

Buske C. Hema­to­lo­gic malignancies-​sixth European con­gress. 26-28 Febru­ary 2010, Can­nes, France. Drugs 2010;13:300-303.

Buske C. Indo­lent lym­phoma in the elderly. Procee­dings of the first inter­na­tio­nal con­fe­rence on Hae­ma­to­lo­gi­cal Mali­gnan­cies in the Elder­ley. Lis­sa­bon, Por­tu­gal, 2010; 5: 67-68.

Mah SM, Buske C. Hum­phries RK, Kuchen­bauer F. miRNA: A pas­sen­ger stran­ded in RNA-​induced silen­cing com­plex? Crit Rev Euka­riot Gene Expr 2010; 20(2): 141-148. Review.

Sch­öler N, Lan­ger C, Döh­ner H, Buske C, Kuchen­bauer F. Serum microR­NAs as a novel class of bio­mar­kers: a com­pre­hen­sive review of the lite­ra­ture. Exp Hema­tol 2010; 38(12): 1126-30. Review.

2009

 
Rao AV, Valk PJ, Met­ze­ler KH, et al. Age-​specific dif­fe­ren­ces in onco­ge­nic pathway dys­re­gu­la­tion and anthracy­cline sen­si­ti­vity in pati­ents with acute mye­loid leuke­mia. J Clin Oncol. 2009;27:5580-5586.

Desh­pande A, Pas­tore A, Desh­pande AJ, et al. 3'UTR media­ted regu­la­tion of the cyclin D1 proto-​oncogene. Cell Cycle. 2009;8:3584-3592.

Met­ze­ler KH, Dufour A, Bent­haus T, et al. ERG expres­sion is an inde­pen­dent pro­gno­stic fac­tor and allows refi­ned risk stra­ti­fi­ca­tion in cyto­ge­ne­ti­cally nor­mal acute mye­loid leuke­mia: a com­pre­hen­sive ana­ly­sis of ERG, MN1, and BAALC tran­script levels using oli­go­nucleo­tide micro­ar­rays. J Clin Oncol. 2009;27:5031-5038.

Desh­pande AJ, Ahmed F, Buske C. Iden­ti­fi­ca­tion of murine and human acute mye­loid leuke­mia stem cells. Methods Mol Biol. 2009;568:21-35.

Heil­meier B, Spie­ker­mann K, Boh­l­an­der S, et al. [Modern leuke­mia dia­gno­sis in adults]. Dtsch Med Wochen­schr. 2009;134:1222-1226.

Lin YH, Kaka­dia PM, Chen Y, et al. Glo­bal reduc­tion of the epi­ge­ne­tic H3K79 methy­la­tion mark and incre­a­sed chro­mo­so­mal insta­bi­lity in CALM-​AF10-​positive leuke­mias. Blood. 2009;114:651-658.

Schnei­der F, Hos­ter E, Unter­halt M, et al. NPM1 but not FLT3-ITD muta­ti­ons pre­dict early blast cell cle­arance and CR rate in pati­ents with nor­mal karyo­type AML (NK-​AML) or high-​risk mye­lo­dys­plastic syn­drome (MDS). Blood. 2009;113:5250-5253.

Reindl C, Quent­meier H, Petro­pou­los K, et al. CBL exon 8/9 mutants acti­vate the FLT3 pathway and clus­ter in core bin­ding fac­tor/11q dele­tion acute mye­loid leuke­mia/mye­lo­dys­plastic syn­drome sub­ty­pes. Clin Can­cer Res. 2009;15:2238-2247.

Thoene S, Rawat VP, Heil­meier B, et al. The home­obox gene CDX2 is aberrantly expres­sed and asso­cia­ted with an infe­rior pro­gno­sis in pati­ents with acute lym­phob­lastic leuke­mia. Leuke­mia. 2009;23:649-655.

Braess J, Spie­ker­mann K, Staib P, et al. Dose-​dense induc­tion with sequen­tial high-​dose cyt­ara­bine and mit­oxan­tone (S-HAM) and peg­fil­gra­stim results in a high effi­cacy and a short dura­tion of cri­ti­cal neu­tro­pe­nia in de novo acute mye­loid leuke­mia: a pilot study of the AMLCG. Blood. 2009;113:3903-3910.

Buske C, Hos­ter E, Drey­ling M, et al. The addi­tion of ritu­xi­mab to front-​line the­rapy with CHOP (R-​CHOP) results in a hig­her response rate and lon­ger time to treat­ment failure in pati­ents with lym­pho­plas­ma­cy­tic lym­phoma: results of a ran­do­mi­zed trial of the Ger­man Low-​Grade Lym­phoma Study Group (GLSG). Leuke­mia. 2009;23:153-161.

2008

Buske C, Gis­sel­brecht C, Grib­ben J, Letai T, McLau­gh­lin P, Wil­son W. Refi­ning the treat­ment of fol­li­cu­lar lym­phoma. Leuk Lym­phoma. 2008;49 Suppl 1:18-26.

Archan­gelo LF, Greif PA, Hol­zel M, et al. The CALM and CALM/AF10 inter­ac­tor CATS is a mar­ker for pro­li­fe­ra­tion. Mol Oncol. 2008;2:356-367.

Met­ze­ler KH, Hum­mel M, Bloom­field CD, et al. An 86-​probe-set gene-​expression signa­ture pre­dicts sur­vi­val in cyto­ge­ne­ti­cally nor­mal acute mye­loid leuke­mia. Blood. 2008;112:4193-4201.

Vem­pati S, Reindl C, Wolf U, et al. Trans­for­ma­tion by onco­ge­nic mutants and ligand-​dependent acti­va­tion of FLT3 wild-​type requi­res the tyro­sine resi­dues 589 and 591. Clin Can­cer Res. 2008;14:4437-4445.

Petro­pou­los K, Arseni N, Sch­essl C, et al. A novel role for Lef-1, a cen­tral tran­scrip­tion media­tor of Wnt signa­ling, in leu­ke­mo­ge­ne­sis. J Exp Med. 2008;205:515-522.

Ahmed F, Arseni N, Glimm H, Hid­de­mann W, Buske C, Feuring-​Buske M. Con­sti­tu­tive expres­sion of the ATP-​binding cas­sette trans­por­ter ABCG2 enhan­ces the growth poten­tial of early human hema­to­poie­tic pro­ge­ni­tors. Stem Cells. 2008;26:810-818.

Rawat VP, Thoene S, Naidu VM, et al. Over­ex­pres­sion of CDX2 per­turbs HOX gene expres­sion in murine pro­ge­ni­tors depen­ding on its N-​terminal domain and is clo­sely cor­re­la­ted with dere­gu­la­ted HOX gene expres­sion in human acute mye­loid leuke­mia. Blood. 2008;111:309-319.

2007

Schmitz N, Buske C, Gis­sel­brecht C. Auto­lo­gous stem cell trans­plan­ta­tion in lym­phoma. Semin Hema­tol. 2007;44:234-245.

Desh­pande AJ, Buske C. Kno­cking the Wnt out of the sails of leuke­mia stem cell deve­lo­p­ment. Cell Stem Cell. 2007;1:597-598.

Buske C, Hid­de­mann W. [The older pati­ent with mali­gnant disea­ses]. Inter­nist (Berl). 2007;48:1206,1208-1210.

Met­ze­ler KH, Braess J, Spie­ker­mann K, et al. [For­tui­tous fin­ding: throm­bo­cy­to­pe­nia and throm­bo­cy­to­sis]. MMW Fort­schr Med. 2007;149:34-35, 37.

Schnei­der F, Boh­l­an­der SK, Schnei­der S, et al. AML1-ETO meets JAK2: cli­ni­cal evi­dence for the two hit model of leu­ke­mo­ge­ne­sis from a mye­lo­pro­li­fe­ra­tive syn­drome pro­gres­sing to acute mye­loid leuke­mia. Leuke­mia. 2007;21:2199-2201.

Kohl TM, Hel­lin­ger C, Ahmed F, et al. BH3 mime­tic ABT-737 neu­tra­li­zes resis­tance to FLT3 inhi­bi­tor treat­ment media­ted by FLT3-​independent expres­sion of BCL2 in pri­mary AML blasts. Leuke­mia. 2007;21:1763-1772.

Frit­sch S, Buske C, Wor­mann B, Wed­ding U, Hid­de­mann W, Spie­ker­mann K. [The­rapy of acute mye­loid leuke­mia (AML) for medi­cally non-​fit pati­ents]. Med Klin (Munich). 2007;102:324-329.

Heil­meier B, Buske C, Spie­ker­mann K, et al. [Dia­gno­stics, clas­si­fi­ca­tion and pro­gno­stic cri­te­ria of acute mye­loid leuke­mia]. Med Klin (Munich). 2007;102:296-308.

Christ O, Feuring-​Buske M, Hid­de­mann W, Buske C. [Pat­ho­bio­logy of acute mye­loid leuke­mia]. Med Klin (Munich). 2007;102:290-295.

Buske C, Hid­de­mann W. [Mali­gnant lymphoma-​-there are still many open ques­ti­ons]. Inter­nist (Berl). 2007;48:349-350.

Desh­pande AJ, Buske C. Lym­phoid pro­ge­ni­tors as can­di­date can­cer stem cells in AML: new per­spec­ti­ves. Cell Cycle. 2007;6:543-545.

Buske C, Unter­halt M, Hid­de­man W. [The­rapy of fol­li­cu­lar lym­phoma]. Inter­nist (Berl). 2007;48:372-381.

Hid­de­mann W, Buske C, Drey­ling M, Wei­gert O, Lenz G, Unter­halt M. Cur­rent manage­ment of fol­li­cu­lar lym­pho­mas. Br J Hae­ma­tol. 2007;136:191-202.

2006

Desh­pande AJ, Cusan M, Rawat VP, et al. Acute mye­loid leuke­mia is pro­pa­ga­ted by a leuke­mic stem cell with lym­phoid cha­rac­te­ristics in a mouse model of CALM/AF10-​positive leuke­mia. Can­cer Cell. 2006;10:363-374.

Frit­sch S, Met­ze­ler K, Hid­de­mann W, Buske C. [Dia­gno­stics and the­rapy of acute mye­loid leuke­mia]. Dtsch Med Wochen­schr. 2006;131:2401-2406.

Kuchen­bauer F, Schnitt­ger S, Look T, et al. Iden­ti­fi­ca­tion of addi­tio­nal cyto­ge­ne­tic and mole­cu­lar gene­tic abnor­ma­li­ties in acute mye­loid leu­ka­e­mia with t(8;21)/AML1-ETO. Br J Hae­ma­tol. 2006;134:616-619.

Wei­gert O, Drey­ling M, Unter­halt M, Hid­de­mann W, Buske C. Inves­ti­ga­tio­nal stra­te­gies in auto­lo­gous stem cell trans­plan­ta­tion for fol­li­cu­lar lym­phoma. Curr Oncol Rep. 2006;8:368-375.

Met­ze­ler K, Frit­sch S, Buske C, Hid­de­mann W. [Acute mye­loid leuke­mia -- on the way towards pathogenesis-​oriented treat­ment]. Dtsch Med Wochen­schr. 2006;131:1466-1468.

Hid­de­mann W, Spie­ker­mann K, Braess J, Feuring-​Buske M, Buske C, Buch­ner T. [Risk-​adapted the­rapy of acute mye­loid leuke­mia]. Inter­nist (Berl). 2006;47 Suppl 1:S33-39.

Buske C, Hid­de­mann W. Ritu­xi­mab main­ten­ance the­rapy in indo­lent NHL: a cli­ni­cal review. Leuk Res. 2006;30 Suppl 1:S11-15.

Buske C, Hos­ter E, Drey­ling M, Has­ford J, Unter­halt M, Hid­de­mann W. The Fol­li­cu­lar Lym­phoma Inter­na­tio­nal Pro­gno­stic Index (FLIPI) sepa­ra­tes high-​risk from intermediate-​ or low-​risk pati­ents with advanced-​stage fol­li­cu­lar lym­phoma trea­ted front-​line with ritu­xi­mab and the com­bi­na­tion of cyclo­phos­pha­mide, doxo­ru­bi­cin, vin­cris­tine, and pred­ni­sone (R-​CHOP) with respect to treat­ment out­come. Blood. 2006;108:1504-1508.

Buske C, Glimm H, Feuring-​Buske M. [Stem cell the­rapy. Bio­logy of hema­to­poie­tic stem cells]. Inter­nist (Berl). 2006;47:459-460, 462-454.

Buske C, Wei­gert O, Drey­ling M, Unter­halt M, Hid­de­mann W. Cur­rent sta­tus and per­spec­tive of anti­body the­rapy in fol­li­cu­lar lym­phoma. Hae­ma­to­lo­gica. 2006;91:104-112.

Feuring-​Buske M, Hart­mann EM, Ott G, Reu­ter H, Buske C, Rosen­wald A. [DNA-​chips in the dia­gno­sis of hema­to­lo­gi­cal mali­gnan­cies]. Inter­nist (Berl). 2006;47:39-46.

2005

Kuchen­bauer F, Feuring-​Buske M, Buske C. AML1-ETO needs a part­ner: new insights into the patho­ge­nesis of t(8;21) leuke­mia. Cell Cycle. 2005;4:1716-1718.

Arseni N, Ahmed F, Hid­de­mann W, Buske C, Feuring-​Buske M. Effects of the pro­tein tyro­sine kinase inhi­bi­tor, SU5614, on leuke­mic and nor­mal stem cells. Hae­ma­to­lo­gica. 2005;90:1577-1578.

Hid­de­mann W, Spie­ker­mann K, Buske C, et al. Towards a pathogenesis-​oriented the­rapy of acute mye­loid leuke­mia. Crit Rev Oncol Hema­tol. 2005;56:235-245.

Drey­ling M, Buske C, Hid­de­mann W. [Up-​to-date treat­ment of fol­li­cu­lar lym­pho­mas]. Dtsch Med Wochen­schr. 2005;130:2149-2154.

Hid­de­mann W, Buske C, Drey­ling M, et al. Treat­ment stra­te­gies in fol­li­cu­lar lym­pho­mas: cur­rent sta­tus and future per­spec­ti­ves. J Clin Oncol. 2005;23:6394-6399.

Sch­essl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length muta­tion col­la­bo­rate in indu­cing acute leuke­mia in mice. J Clin Invest. 2005;115:2159-2168.

Drey­ling M, Buske C, Hid­de­mann W. Advan­ces in mole­cu­lar bio­logy dia­gno­stic and treat­ment of B-​cell mali­gnan­cies: indo­lent B-​cell lym­phoma. Ann Oncol. 2005;16 Suppl 2:ii99-104.

Buske C, Drey­ling M, Unter­halt M, Hid­de­mann W. Trans­plan­ta­tion stra­te­gies for pati­ents with fol­li­cu­lar lym­phoma. Curr Opin Hema­tol. 2005;12:266-272.

Buske C, Drey­ling M, Unter­halt M, Hid­de­mann W. [Mono­clo­nal anti­body the­rapy for mali­gnant lym­phoma]. Med Klin (Munich). 2005;100:14-24. 

2004- 2000

Buske C, Drey­ling M, Unter­halt M, Hid­de­mann W. [Mono­clo­nal anti­body treat­ment of mali­gnant lym­phoma]. Inter­nist (Berl). 2004;45:1370-1377.

Buske C, Drey­ling H, Unter­halt M, Hid­de­mann W. Novel treat­ment stra­te­gies in fol­li­cu­lar lym­phoma. Ann Hema­tol. 2004;83 Suppl 1:S72.

Rawat VP, Cusan M, Desh­pande A, et al. Ecto­pic expres­sion of the home­obox gene Cdx2 is the trans­forming event in a mouse model of t(12;13)(p13;q12) acute mye­loid leuke­mia. Proc Natl Acad Sci U S A. 2004;101:817-822.

Pineault N, Buske C, Feuring-​Buske M, et al. Induc­tion of acute mye­loid leuke­mia in mice by the human leukemia-​specific fusion gene NUP98-HOXD13 in con­cert with Meis1. Blood. 2003;101:4529-4538.

Spie­ker­mann K, Dir­schin­ger RJ, Schwab R, et al. The pro­tein tyro­sine kinase inhi­bi­tor SU5614 inhi­bits FLT3 and indu­ces growth arrest and apo­pto­sis in AML-​derived cell lines expres­sing a con­sti­tu­tively acti­va­ted FLT3. Blood. 2003;101:1494-1504.

Feuring-​Buske M, Hid­de­mann W, Buske C. [Patho­ge­nesis and bio­logy of leuke­mias]. Inter­nist (Berl). 2002;43:1179-1189.

Buske C, Hid­de­mann W. [Acute and chro­nic leuke­mias. Cur­rent aspects of patho­ge­nesis, dia­gno­sis and the­rapy]. Inter­nist (Berl). 2002;43:1177-1178.

Buske C, Feuring-​Buske M, Abra­mo­vich C, et al. Dere­gu­la­ted expres­sion of HOXB4 enhan­ces the pri­mi­tive growth acti­vity of human hema­to­poie­tic cells. Blood. 2002;100:862-868.

Blaschke S, Han­nig H, Buske C, Kaup FJ, Huns­mann G, Bode­mer W. Expres­sion of the simian Epstein-​Barr virus-​encoded latent mem­brane protein-​1 in mali­gnant lym­pho­mas of SIV-​infected rhe­sus maca­ques. J Med Virol. 2001;65:114-120.

Buske C, Feuring-​Buske M, Anton­chuk J, et al. Over­ex­pres­sion of HOXA10 per­turbs human lym­pho­mye­lo­poie­sis in vitro and in vivo. Blood. 2001;97:2286-2292.

Buske C, Hum­phries RK. Home­obox genes in leu­ke­mo­ge­ne­sis. Int J Hema­tol. 2000;71:301-308.